Protembis GmbH (Protembis) has completed a €30 million Series B financing round to help fund enrollment in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial. Structured in two separate capital increases, the funding round was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund.

Protembis GmbH（Protembis）已完成3000万欧元的B系列融资回合，以帮助资助参加PROTEMBO研究设备豁免（IDE）关键试验。这轮融资分为两次单独增资，由欧洲风险投资财团共同牵头，该财团包括瑞典的Segulah Medical Acceleration、意大利的XGEN Venture和德国的TechVision Fund。

Other supporters included Coparion, several large family offices, angel investors, and a multinational medical device strategic..

其他支持者包括Coparion、几家大型家族理财办公室、天使投资者和一家跨国医疗器械战略公司。。

“We are delighted to complete the round and would like to thank our existing investors as well as the new investors for their trust and confidence,” Protembis Co-CEOs Karl von Mangoldt and Conrad Rasmus said. “It reflects the fact the field of cerebral embolic protection is buoyant, and that future growth will be driven by younger and lower risk patients who have zero tolerance for brain injury risk when selecting to undergo transcatheter aortic valve replacement.”.

Protembis联合首席执行官卡尔·冯·曼戈尔特（KarlvonMangoldt）和康拉德·拉斯姆斯（ConradRasmus）表示：“我们很高兴完成这一轮投资，并感谢现有投资者和新投资者的信任和信心。”。“这反映了脑栓塞保护领域蓬勃发展的事实，未来的增长将由年轻和低风险的患者驱动，这些患者在选择接受经导管主动脉瓣置换术时对脑损伤风险没有耐受性。”。

In addition to announcing the funding, Protembis named Keith D. Dawkins, M.D., to its Board of Directors. Dawkins has more than 35 years’ experience in the cardiovascular environment, having spent over two decades as a practicing interventional cardiologist in the United Kingdom. He has held research roles as a Fulbright Scholar at Stanford University, served as president of the British Cardiovascular Intervention Society, and authored more than 750 academic publications and presentations.

除了宣布资金外，Protembis还任命医学博士Keith D.Dawkins为董事会成员。道金斯在心血管环境方面拥有超过35年的经验，在英国担任了20多年的执业介入心脏病专家。他曾担任斯坦福大学富布赖特学者的研究角色，曾担任英国心血管干预学会主席，并撰写了750多篇学术出版物和演讲稿。

Dawkins has been chief medical officer (CMO) of Shockwave Medical since 2019; before that, he was global CMO at Boston Scientific Corp., where he worked in senior positions since his 2008 hiring. He also serves as a member of the boards of Ventric Health LLC and JenaValve Technology Inc., as well as chairman of InnovHeart s.r.l..

自2019年以来，道金斯一直担任Shockwave medical的首席医疗官（CMO）；在此之前，他是波士顿科学公司（Boston Scientific Corp.）的全球首席营销官，自2008年被聘用以来，一直担任高级职位。他还担任Ventric Health LLC和JenaValve Technology Inc.的董事会成员，以及InnovHeart s.r.l.的董事长。。

“To have such a visionary leader as Dr. Dawkins join our Board of Directors is an exciting indication of the opportunities that cerebral embolic protection holds for future transcatheter therapies. We look forward to close collaboration as the field develops,” Protembis Board Chair Azin Parhizgar, Ph.D., stated..

Protembis董事会主席Azin Parhizgar博士表示：“有Dawkins博士这样一位有远见的领导者加入我们的董事会，这是一个令人兴奋的迹象，表明脑栓塞保护为未来的经导管治疗提供了机会。我们期待着随着该领域的发展而密切合作。”。。

Dawkins will use his expertise to shape Protembis's clinical strategies and pre-commercial programs as the IDE study reaches its conclusion.

随着IDE研究得出结论，道金斯将利用他的专业知识来制定Protembis的临床策略和商业前期计划。

“As a believer in the need to protect the brain from all new lesions during transcatheter aortic valve replacement, I am pleased to join Protembis,” Dawkins said. “The ProtEmbo System and the clinical trial design are both novel and I am confident they will be disruptive to the field of cerebral embolic protection, removing or mitigating many of the current issues that concern the physician community.”.

道金斯说：“作为经导管主动脉瓣置换术中需要保护大脑免受所有新病变的信徒，我很高兴加入Protembis。”。“ProtEmbo系统和临床试验设计都是新颖的，我相信它们将对脑栓塞保护领域产生破坏性影响，消除或减轻医生界目前关注的许多问题。”。

The ProtEmbo Cerebral Protection System is an intra-aortic filter device that protects the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). It is a low-profile non thrombogenic system that shields all cerebral vessels, delivered through the left radial artery for optimal placement and stability.

ProtEmbo大脑保护系统是一种主动脉内过滤装置，可保护整个大脑免受经导管主动脉瓣置换术（TAVR）期间释放的栓塞物质的影响。它是一种低姿态的非血栓形成系统，可屏蔽所有脑血管，通过左桡动脉输送，以获得最佳位置和稳定性。

This is an ideal access site enabling physicians to avoid interference with TAVR equipment typically delivered through the femoral artery. .

这是一个理想的进入部位，使医生能够避免干扰通常通过股动脉输送的TAVR设备。。

Protembis is a privately held emerging medical device company that has developed the ProtEmbo Cerebral Protection System. The ProtEmbo System is currently undergoing clinical investigations.

Protembis是一家私营新兴医疗器械公司，开发了ProtEmbo大脑保护系统。ProtEmbo系统目前正在进行临床研究。